Talenom Oyj (0RQI)
London Stock Exchange · UK · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 1.090 |
|---|---|
| 52-week range | 1.080 – 2.189 |
| Return, 1 month / 3 months | −7.8% / −8.7% |
| Return, 1 year / 3 years | −46.2% / −63.0% |
| Trend | Below its 200-day average |
| RSI (14) | 39 |
| Volatility (1 year) | 37.1% |
| Worst drawdown (1 year) | -52.7% |
| Average daily value traded | 0.00M EUR |
| Dividend yield | 8.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Talenom Oyj is a Finnish accounting and bookkeeping company based in Oulu. It provides bookkeeping, payroll, tax and financial advisory services, mainly to small and medium-sized businesses, and it also develops and offers software for accounting and invoicing. Its customers are entrepreneurs and companies that outsource their financial administration, and its services are delivered through its own offices and digital tools.
Talenom Oyj trades under the code 0RQI on the London Stock Exchange in UK, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Talenom Oyj (0RQI) trades on the London Stock Exchange in UK. It last closed at EUR 1.090 on 27 October 2026.
Its price-based Market X-Ray is 25 out of 100 (a weak price profile), ranking 3,242 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 46.2% and over the last three months it fell 8.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 16 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -19.2% | ||
| From 52-week high | -50.2% | ||
| Momentum | 21 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -8.7% | ||
| 6-month return | -14.6% | ||
| 12-month return, skipping the last month | -41.6% | ||
| Stability (higher is calmer) | 32 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 37.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -52.7% | ||
| Liquidity | 10 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.00M EUR | ||
| Zero-volume days | 1.7% | ||
| Income | 68 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 8.9% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −1.8% |
|---|---|
| 1 month | −7.8% |
| 3 months | −8.7% |
| 6 months | −14.6% |
| 1 year | −46.2% |
| 3 years | −63.0% |
| 5 years | −86.3% |
Signals
| 50-day / 200-day average | 1.226 / 1.350 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 0.031 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 24 Apr 2026 | EUR 0.0300 |
| 13 Nov 2025 | EUR 0.0669 |
| 20 Mar 2025 | EUR 0.0669 |
| 18 Mar 2024 | EUR 0.1272 |
| 17 Mar 2023 | EUR 0.1205 |
| 4 Mar 2022 | EUR 0.1138 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.